New analysis from the healthcare outsourcing company finds that non-emergency medical transportation providers lose the most revenue in back-office operations — unanswered calls, dispatch gaps, and broker-compliance issues — rather than on the road.

Vancouver, WA, United States, 1st Sep 2026, Grand Newswire – SS Support Network LLC, a U.S.-registered healthcare and non-emergency medical transportation (NEMT) back-office outsourcing company founded in 2020, today released its 2026 NEMT Back-Office Report and announced a free operations audit for U.S. transportation providers. Drawn from the company’s work across more than 200 clients and over 200,000 processed claims, the report identifies where NEMT providers lose trips, revenue, and broker trust, and finds that the costliest failures occur in back-office operations rather than in vehicles or drivers.

The report arrives as demand for medical transportation rises and broker requirements tighten. Industry data places the U.S. NEMT market at roughly $17 billion with mid-single-digit annual growth, while U.S. Census Bureau projections indicate 73.1 million Americans will be aged 65 or older by 2030. Published industry analyses estimate NEMT driver turnover above 64% annually and put the cost of missed medical appointments to the U.S. healthcare system at approximately $150 billion per year, with transportation barriers among the leading contributors.

According to the report, most providers focus on vehicles and drivers while the largest financial losses occur elsewhere: after-hours calls sent to voicemail, will-call returns left unmanaged, broker portals worked inconsistently, and credentials that lapse unnoticed until trips stop or an audit occurs. SS Support Network states that these gaps reduce trip volume, weaken broker relationships, and lower customer satisfaction even when a provider’s fleet and drivers perform well.

The company reports measurable results from its own engagements. In anonymized client outcomes, SS Support Network released $28,000 in previously held Modivcare billing for payment, generated approximately $9,800 in new broker-driven revenue for another provider within about two months, and helped raise one transportation company’s public review rating from 1.8 to 3.7 through consistent, in-name customer support. In a separate engagement, an East Coast NEMT provider transferred its full back office to the company and expanded from a single state to multiple states while SS Support Network continued to manage day-to-day operations for more than two years.

“Most NEMT owners assume their problem is vehicles and drivers,” said Nimra Khalid, Co-Founder & Chief Operating Officer of SS Support Network. “In our experience, the revenue is usually lost in quieter places — a phone going to voicemail overnight, a broker portal left untouched, a credential that expired. When the back office is corrected, the same fleet completes more trips and retains more broker business.”

Alongside the report, SS Support Network is making a free operations audit available to U.S. NEMT providers. The audit is a written review of a provider’s calls, dispatching, scheduling, and broker activity that identifies specific operational issues and recommended corrections, provided at no cost. The company’s agents are HIPAA-trained and operate under a signed Business Associate Agreement (BAA), working within a provider’s existing dispatch software and broker portals, including Modivcare, MTM, and Access2Care.

“Operators should be able to see where they are losing money, in writing,” Nimra added. “If we are not the right fit, the audit says so.”

The 2026 NEMT Back-Office Report and details of the free operations audit are available at https://sssupportnetwork.llc/.

About SS Support Network
SS Support Network LLC is a U.S.-registered business process outsourcing (BPO) company founded in 2020 and headquartered in Vancouver, Washington. The company provides back-office operations for healthcare and transportation businesses, including 24/7 call handling, NEMT dispatch, patient scheduling, medical billing, and provider credentialing, delivered by HIPAA-trained teams serving clients across all 50 U.S. states. More information is available at https://sssupportnetwork.llc.

Media Contact

Organization: SS Support Network

Contact
Person: SS Support Network

Website:

https://sssupport.net

Email:

info@sssupport.net

Address:9407 NE Vancouver Mall Dr

City: Vancouver

State: WA

Country:United States

The post SS Support Network Releases 2026 NEMT Back-Office Report and Launches Free Operations Audit for U.S. Providers
appeared first on Grand Newswire.
It is provided by a third-party content provider. Grand Newswire makes no
warranties or representations in connection with it.

Australia, 1st Sep 2026, Grand Newswire –
 

The Chrysalis BREW Project has announced the winners of the BREW Children’s Book Excellence Award 2026, recognising four children’s books across travel fiction, picture books, fantasy and bilingual literature.

The 2026 recipients are:

• Travel Fiction: Kiera & Lamby: Tokyo by Nicole O’Connor
• Children’s Picture Book: Bartholomew the Badger Listens Closely by Shanela Parvez
• Fantasy: Journey to Superhero School by Gracie Dix
• Bilingual Children’s Literature: Pablo by Mar Andersons

The selected books span different settings, genres and storytelling approaches while sharing an emphasis on imagination, discovery and experiences relevant to young readers.

In Kiera & Lamby: Tokyo, Nicole O’Connor takes young readers on an imaginative journey through Tokyo, incorporating elements of Japanese culture and travel.

Shanela Parvez’s Bartholomew the Badger Listens Closely centres on Lulu, a young hedgehog whose ability to notice what others overlook becomes important when her community faces an approaching storm. 

Journey to Superhero School by Gracie Dix follows young siblings discovering their unusual abilities and learning to manage the challenges that come with them, combining fantasy and family-centred storytelling.

Mar Andersons’s Pablo receives recognition in the Bilingual Children’s Literature category for its focus on language, culture and connections between different communities through children’s storytelling.

More details about this announcement can be found at The Chrysalis BREW Project’s website. 

About the BREW Children’s Book Excellence Award

The BREW Children’s Book Excellence Award is a literary recognition presented by The Chrysalis BREW Project to acknowledge notable children’s books across a range of genres and categories. The award considers the qualities that contribute to an engaging and meaningful reading experience for young audiences, including storytelling, creativity, presentation and relevance to children.

About The Chrysalis BREW Project

The Chrysalis BREW Project is an independent literary and arts platform that publishes book reviews, literary features, interviews and other creative work. Through its editorial and recognition programmes, BREW provides a space for writers, artists and creators to share their work and receive literary attention. The project also presents a range of international book, blog, and poetry awards recognising works across different genres and forms.

Media Contact

Organization: The Chrysalis BREW Project

Contact
Person: The Chrysalis BREW Project

Website:

https://thechrysalisbrewproject.com/

Email:

info@thechrysalisbrewproject.com

Country:Australia

The post BREW Children’s Book Excellence Award 2026 Winners Announced
appeared first on Grand Newswire.
It is provided by a third-party content provider. Grand Newswire makes no
warranties or representations in connection with it.

London, London, September 1st, 2026, Chainwire

ALKEMYA METACORE SCSp SECURES INITIAL USD 50 MILLION INVESTMENT AHEAD OF LISTING OF TOKENISED EQUITY NICKEL OFFERING

Alkemya Luxembourg S.à.r.l. (“Alkemya”), the sponsor, is pleased to announce that Alkemya Metacore SCSp has secured USD 50 million in a pre-launch capital raise for its precision industrial nickel wire business backed by Class 1 nickel wire. It is announcing the sale of additional ALKN tokens in a new tranche (the “Token”) at USD 1.0 per Token. 

The offer, which is being arranged by Hanover Square Capital (UK) Ltd, will take place on Bitfinex Securities. The offer is available to institutional and professional investors and will close on 15 October 2026.

The Tokens are issued by Alkemya Metacore SCSp (“Alkemya Metacore”), a special limited partnership based in Luxembourg, which is registered as an Issuer with CNAD (National Commission of Digital Assets) in El Salvador. 

Alkemya Metacore is a Luxembourg-based investment and operating platform focused on the industrial development, commercialisation, and financial structuring of high-technology metals. It owns approximately 7 million metres of 99.99% ultra-pure nickel wire with 0.025 mm diameter, which has been independently verified and valued at approximately USD 1.64 billion. The asset is held in institutional custody in Lugano, Switzerland.

Alkemya will use part of the initial capital raise and further funds raised in additional tranches to invest working capital in Alkemya Metacore to finance its commercialisation strategy of transforming its ultra-pure wire into engineered mesh products tailored to high-growth applications across seven sectors: EMI shielding, aerospace and defence, marine and desalination, power and industrials, semiconductors, green hydrogen and rare/precious metals recovery. 

The successful capital raise, before secondary market listing, represents a major milestone for the offering and demonstrates confidence in the underlying exposure to high-purity nickel and the structure of the issue. The Token affords investors a combination of an asset-backed investment and a thematic play on energy transition and electronic security technologies.

The listing on Bitfinex Securities of the Token will enable Alkemya to leverage tokenisation to access a wider pool of global investors and be part of a regulated, 24/7 trading venue.

The Tokens aim to provide long-term investment value linked to real-world applications and technology. 

Cash distributions will be governed by a strict waterfall that first returns investor capital in full, cumulative distributions equal to a 6% per annum compound interest calculated annually (i.e., the preferred return) on the investor capital at any time outstanding, from the date of payment of the same up to the date of final repayment of the invested capital and an additional 80/20 profit split with a carry partner in favour of Token holders from the commercial business. 

Carlo Guido Della Peruta, Manager of the General Partner of Alkemya Metacore, commented: “Securing this initial investment is a significant milestone for Alkemya and validates both the quality of our asset and the strength of our commercialisation strategy. We chose to list on Bitfinex Securities because tokenisation offers us access to a genuinely global investor base within a regulated framework, and because it reflects the innovative approach we are taking across all aspects of our business. This raise will allow us to begin transforming our nickel wire asset into high-value engineered products serving some of the fastest-growing sectors in the global economy, and we look forward to welcoming further investors as the listing progresses.” 

Jesse Knutson, Head of Operations at Bitfinex Securities, commented: “Bitfinex Securities exists to connect exciting investment opportunities with a broader and deeper investor base, giving more people access to investments that were previously out of reach and giving businesses access to a wider pool of capital. Alkemya Metacore will represent yet another example of how we’re using blockchain technology to bring previously inaccessible asset classes to market within stringent regulatory guardrails, and Alkemya’s initial $50 million capital raise is a sign of appetite for this exciting opportunity.”

Arvinder Sood, CEO and Director at Hanover Square Capital (UK) Ltd, said: “Hanover Square Capital is delighted to announce this transaction in collaboration with Bitfinex Securities and its successful pre-launch close of USD 50 million investment, which not only underscores the evolving direction of global capital markets but also establishes a compelling foundation for a groundbreaking transaction with the launch of ALKN tokens. This milestone reflects a broader structural shift in how financial assets are created, accessed, and exchanged, as traditional frameworks increasingly converge with digital innovation. By embracing tokenised equity, the transaction highlights a more efficient, transparent, and accessible model for capital formation, one that is better aligned with the demands of modern investors and issuers alike, with the capacity to trade on a peer-to-peer basis.

Hanover Square Capital believes that this transaction not only validates that trajectory but also signals the growing importance of blockchain-enabled solutions in redefining how assets are issued, managed, and traded on a global scale.”

Bitfinex Securities provides a regulated venue for the issuance and trading of tokenised securities, combining blockchain technology with regulated market access for issuers and eligible investors.

The offering was advised by the following law firms: CMS DeBacker in Luxembourg (as regards Luxembourg law aspects), Dentons El Salvador (as regards El Salvador law aspects), Foley and Lardner in the US (as regards US law aspects), and CNPLaw LLP in Singapore (as regards Singapore law aspects). Winston Taylor acted for Bitfinex Securities. The Edison Group advised on investor relations and issued a pre-IPO research note. The ALKN tokens will be available for trading across three regulated exchanges: Bitfinex Securities, AGX (operated by LabyrinthX Technologies Pte Ltd, a company in the Hydra X group) and Archax Ltd. HydraX Digital Assets Pte. Ltd. is the custodian and distribution partner in Asia, with Archax playing a similar role in the UK. Scytale, the technology firm, is providing onboarding technology services for compliance to Alkemya Metacore under Luxembourg and EU law.

About Hanover

Hanover Square Capital (UK) Ltd (“HSC”) is an independent, regulated advisory firm headquartered in London, comprising a small team of highly experienced finance professionals. The firm provides strategic advice across a broad range of areas, including energy transition and climate-related solutions, public and private debt and equity placements, bank financing, and both project and commodity finance, alongside advisory services on financial investments. HSC brings deep sector expertise spanning environment-related projects, infrastructure development, next-generation technologies with applications to electromagnetic shielding and efficient green energy production, with a particular emphasis on sustainability and the global energy transition.

As a member of the UK Sustainable Investment and Finance Association (UKSIF), the firm is closely aligned with leading sustainability practices. Its client base is global, encompassing large and mid-cap corporations, government and state agencies, selected institutional investors, and professional investors. HSC is further supported by its connected company, Hanover Square Investments Pte. Ltd, based in Singapore.

About Bitfinex Securities

Bitfinex Securities provides a regulated platform for the issuance, listing and trading of tokenised securities. Licensed in El Salvador and Kazakhstan, Bitfinex Securities gives issuers and eligible investors access to digital securities markets within established regulatory frameworks.

The platform supports capital raising and secondary market trading for tokenised securities, including real-world asset-linked opportunities. By combining market infrastructure, technology and regulatory oversight, Bitfinex Securities aims to make capital formation more efficient, transparent and accessible for issuers and investors.

Media Contact:

Richard Morgan Evans

rmorganevans@sapiencecomms.co.uk

Jonathan Batchelor

jbatchelor@sapiencecomms.co.uk

Sapience Communications

+44 (0) 203 841 7610

Disclaimer:

No offering is being made in the European Union or the European Economic Area, and no retail investors within the meaning of Directive 2014/65/EU (as amended, “MiFID II”) will be admitted as purchasers of the ALKN Tokens. The ALKN Tokens are also exempt from the obligation to publish a prospectus for offers to the public under Regulation (EU) 2017/1129, as amended (the “Prospectus Regulation”), as the offering will only be addressed to qualified investors in the EEA/EU. The offering is limited to institutional investors in Singapore. This news release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of any of the ALKN Tokens in any jurisdiction in which such offer, solicitation or sale would be unlawful. These securities have not been and will not be registered under the US Securities Act of 1933, as amended (the “Securities Act”), the securities laws of any U.S. state or the securities laws of any other jurisdiction outside El Salvador, nor is such registration contemplated. The ALKN Tokens will only be offered and sold outside the United States (as defined in Regulation S under the Securities Act (“Regulation S”)) in offshore transactions pursuant to Rule 903 or Rule 904 of Regulation S and in accordance with any other applicable securities laws where such offers and sales are made. The ALKN Tokens have not been and will not be offered or sold within the United States. 

Forward-Looking Statements: Information outlined in this news release may involve forward-looking statements under applicable securities laws. The forward-looking statements contained herein are expressly qualified in their entirety by this cautionary statement. The forward-looking statements included in this document are made as of the date of this document, and Alkemya Metacore and Alkemya disclaim any intention or obligation to update or revise any forward-looking statements, whether because of new information, future events or otherwise, except as expressly required by applicable securities legislation. Although management believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct.

Notice: None of Bitfinex Securities, Archax Ltd or the Hydra X group accepts responsibility for the adequacy or accuracy of this news release.

Since this offering is not targeting US investors as it is made under Regulation S and similarly it is not targeting EU retail investors under the EU Directive 2014/65/EU (as amended, “MiFID II”) or non-institutional investors in Singapore, this announcement is not intended for US investors, retail investors in the EU or non-institutional investors in Singapore. US investors, EU retail investors and non-institutional investors in Singapore are considered prohibited investors under the ALKN Token offering. 

Contact

Jonathan Batchelor
Sapience
jbatchelor@sapiencecomms.co.uk

London, London, September 1st, 2026, Chainwire

ALKEMYA METACORE SCSp SECURES INITIAL USD 50 MILLION INVESTMENT AHEAD OF LISTING OF TOKENISED EQUITY NICKEL OFFERING

Alkemya Luxembourg S.à.r.l. (“Alkemya”), the sponsor, is pleased to announce that Alkemya Metacore SCSp has secured USD 50 million in a pre-launch capital raise for its precision industrial nickel wire business backed by Class 1 nickel wire. It is announcing the sale of additional ALKN tokens in a new tranche (the “Token”) at USD 1.0 per Token. 

The offer, which is being arranged by Hanover Square Capital (UK) Ltd, will take place on Bitfinex Securities. The offer is available to institutional and professional investors and will close on 15 October 2026.

The Tokens are issued by Alkemya Metacore SCSp (“Alkemya Metacore”), a special limited partnership based in Luxembourg, which is registered as an Issuer with CNAD (National Commission of Digital Assets) in El Salvador. 

Alkemya Metacore is a Luxembourg-based investment and operating platform focused on the industrial development, commercialisation, and financial structuring of high-technology metals. It owns approximately 7 million metres of 99.99% ultra-pure nickel wire with 0.025 mm diameter, which has been independently verified and valued at approximately USD 1.64 billion. The asset is held in institutional custody in Lugano, Switzerland.

Alkemya will use part of the initial capital raise and further funds raised in additional tranches to invest working capital in Alkemya Metacore to finance its commercialisation strategy of transforming its ultra-pure wire into engineered mesh products tailored to high-growth applications across seven sectors: EMI shielding, aerospace and defence, marine and desalination, power and industrials, semiconductors, green hydrogen and rare/precious metals recovery. 

The successful capital raise, before secondary market listing, represents a major milestone for the offering and demonstrates confidence in the underlying exposure to high-purity nickel and the structure of the issue. The Token affords investors a combination of an asset-backed investment and a thematic play on energy transition and electronic security technologies.

The listing on Bitfinex Securities of the Token will enable Alkemya to leverage tokenisation to access a wider pool of global investors and be part of a regulated, 24/7 trading venue.

The Tokens aim to provide long-term investment value linked to real-world applications and technology. 

Cash distributions will be governed by a strict waterfall that first returns investor capital in full, cumulative distributions equal to a 6% per annum compound interest calculated annually (i.e., the preferred return) on the investor capital at any time outstanding, from the date of payment of the same up to the date of final repayment of the invested capital and an additional 80/20 profit split with a carry partner in favour of Token holders from the commercial business. 

Carlo Guido Della Peruta, Manager of the General Partner of Alkemya Metacore, commented: “Securing this initial investment is a significant milestone for Alkemya and validates both the quality of our asset and the strength of our commercialisation strategy. We chose to list on Bitfinex Securities because tokenisation offers us access to a genuinely global investor base within a regulated framework, and because it reflects the innovative approach we are taking across all aspects of our business. This raise will allow us to begin transforming our nickel wire asset into high-value engineered products serving some of the fastest-growing sectors in the global economy, and we look forward to welcoming further investors as the listing progresses.” 

Jesse Knutson, Head of Operations at Bitfinex Securities, commented: “Bitfinex Securities exists to connect exciting investment opportunities with a broader and deeper investor base, giving more people access to investments that were previously out of reach and giving businesses access to a wider pool of capital. Alkemya Metacore will represent yet another example of how we’re using blockchain technology to bring previously inaccessible asset classes to market within stringent regulatory guardrails, and Alkemya’s initial $50 million capital raise is a sign of appetite for this exciting opportunity.”

Arvinder Sood, CEO and Director at Hanover Square Capital (UK) Ltd, said: “Hanover Square Capital is delighted to announce this transaction in collaboration with Bitfinex Securities and its successful pre-launch close of USD 50 million investment, which not only underscores the evolving direction of global capital markets but also establishes a compelling foundation for a groundbreaking transaction with the launch of ALKN tokens. This milestone reflects a broader structural shift in how financial assets are created, accessed, and exchanged, as traditional frameworks increasingly converge with digital innovation. By embracing tokenised equity, the transaction highlights a more efficient, transparent, and accessible model for capital formation, one that is better aligned with the demands of modern investors and issuers alike, with the capacity to trade on a peer-to-peer basis.

Hanover Square Capital believes that this transaction not only validates that trajectory but also signals the growing importance of blockchain-enabled solutions in redefining how assets are issued, managed, and traded on a global scale.”

Bitfinex Securities provides a regulated venue for the issuance and trading of tokenised securities, combining blockchain technology with regulated market access for issuers and eligible investors.

The offering was advised by the following law firms: CMS DeBacker in Luxembourg (as regards Luxembourg law aspects), Dentons El Salvador (as regards El Salvador law aspects), Foley and Lardner in the US (as regards US law aspects), and CNPLaw LLP in Singapore (as regards Singapore law aspects). Winston Taylor acted for Bitfinex Securities. The Edison Group advised on investor relations and issued a pre-IPO research note. The ALKN tokens will be available for trading across three regulated exchanges: Bitfinex Securities, AGX (operated by LabyrinthX Technologies Pte Ltd, a company in the Hydra X group) and Archax Ltd. HydraX Digital Assets Pte. Ltd. is the custodian and distribution partner in Asia, with Archax playing a similar role in the UK. Scytale, the technology firm, is providing onboarding technology services for compliance to Alkemya Metacore under Luxembourg and EU law.

About Hanover

Hanover Square Capital (UK) Ltd (“HSC”) is an independent, regulated advisory firm headquartered in London, comprising a small team of highly experienced finance professionals. The firm provides strategic advice across a broad range of areas, including energy transition and climate-related solutions, public and private debt and equity placements, bank financing, and both project and commodity finance, alongside advisory services on financial investments. HSC brings deep sector expertise spanning environment-related projects, infrastructure development, next-generation technologies with applications to electromagnetic shielding and efficient green energy production, with a particular emphasis on sustainability and the global energy transition.

As a member of the UK Sustainable Investment and Finance Association (UKSIF), the firm is closely aligned with leading sustainability practices. Its client base is global, encompassing large and mid-cap corporations, government and state agencies, selected institutional investors, and professional investors. HSC is further supported by its connected company, Hanover Square Investments Pte. Ltd, based in Singapore.

About Bitfinex Securities

Bitfinex Securities provides a regulated platform for the issuance, listing and trading of tokenised securities. Licensed in El Salvador and Kazakhstan, Bitfinex Securities gives issuers and eligible investors access to digital securities markets within established regulatory frameworks.

The platform supports capital raising and secondary market trading for tokenised securities, including real-world asset-linked opportunities. By combining market infrastructure, technology and regulatory oversight, Bitfinex Securities aims to make capital formation more efficient, transparent and accessible for issuers and investors.

Media Contact:

Richard Morgan Evans

rmorganevans@sapiencecomms.co.uk

Jonathan Batchelor

jbatchelor@sapiencecomms.co.uk

Sapience Communications

+44 (0) 203 841 7610

Disclaimer:

No offering is being made in the European Union or the European Economic Area, and no retail investors within the meaning of Directive 2014/65/EU (as amended, “MiFID II”) will be admitted as purchasers of the ALKN Tokens. The ALKN Tokens are also exempt from the obligation to publish a prospectus for offers to the public under Regulation (EU) 2017/1129, as amended (the “Prospectus Regulation”), as the offering will only be addressed to qualified investors in the EEA/EU. The offering is limited to institutional investors in Singapore. This news release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of any of the ALKN Tokens in any jurisdiction in which such offer, solicitation or sale would be unlawful. These securities have not been and will not be registered under the US Securities Act of 1933, as amended (the “Securities Act”), the securities laws of any U.S. state or the securities laws of any other jurisdiction outside El Salvador, nor is such registration contemplated. The ALKN Tokens will only be offered and sold outside the United States (as defined in Regulation S under the Securities Act (“Regulation S”)) in offshore transactions pursuant to Rule 903 or Rule 904 of Regulation S and in accordance with any other applicable securities laws where such offers and sales are made. The ALKN Tokens have not been and will not be offered or sold within the United States. 

Forward-Looking Statements: Information outlined in this news release may involve forward-looking statements under applicable securities laws. The forward-looking statements contained herein are expressly qualified in their entirety by this cautionary statement. The forward-looking statements included in this document are made as of the date of this document, and Alkemya Metacore and Alkemya disclaim any intention or obligation to update or revise any forward-looking statements, whether because of new information, future events or otherwise, except as expressly required by applicable securities legislation. Although management believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct.

Notice: None of Bitfinex Securities, Archax Ltd or the Hydra X group accepts responsibility for the adequacy or accuracy of this news release.

Since this offering is not targeting US investors as it is made under Regulation S and similarly it is not targeting EU retail investors under the EU Directive 2014/65/EU (as amended, “MiFID II”) or non-institutional investors in Singapore, this announcement is not intended for US investors, retail investors in the EU or non-institutional investors in Singapore. US investors, EU retail investors and non-institutional investors in Singapore are considered prohibited investors under the ALKN Token offering. 

Contact

Jonathan Batchelor
Sapience
jbatchelor@sapiencecomms.co.uk

Why Mr. IBILE Is Strategically Positioning for the Future of New Lagos

Nigeria, 1st Sep 2026 – “A conventional developer builds where the city already is. A strategist studies where the city is going and begins building there.”

Lagos has never been a city that waits for the future.

It expands, transforms, and reinvents itself, often years before the rest of the country fully recognizes where the next wave of opportunity is taking shape.

And increasingly, one name is becoming synonymous with understanding that movement from the ground up: Hon. (Dr.) Saheed Mosadoluwa Audullahi, popularly known as Mr. IBILE, the “Lagos Landlord.”

As Executive Managing Director and CEO of Harmony Garden & Estate Development Ltd., Dr. Mosadoluwa is building more than estates. He is pursuing a larger proposition: to identify where Lagos is going, position land and communities around that trajectory, and create places capable of participating in the city’s next era of growth.

From Aviation to Land: Learning to Read Movement

Perhaps the most interesting dimension of Mosadoluwa’s real-estate philosophy is that his story did not begin with property.

His professional journey spans aviation, logistics, international trade, and entrepreneurship. In 2011, he became the first Black man appointed to the board of the Ras Khaimah Movers Association in the UAE, an achievement that reflected his expertise in aviation and freight logistics.

That background matters.

Aviation and logistics teach a fundamental lesson: location is never simply about where something is; it is about where movement is going.

Airports, highways, ports, industrial clusters, commercial districts and residential communities do not develop independently. They create interconnected economic ecosystems.

This is the lens through which Mosadoluwa appears to approach land.

Rather than viewing a parcel simply as land to be sold, his strategy places increasing emphasis on corridors, infrastructure, accessibility, community development, and the economic activity that follows them.

That philosophy is particularly visible in Harmony Garden’s concentration across the rapidly developing Lekki–Ibeju-Lekki corridor.

The New Lagos Is Moving East

For decades, Lagos’ traditional centres of economic gravity were concentrated around Lagos Island, Victoria Island, Ikoyi, Ikeja and other established districts.

But the city’s next chapter is increasingly being written along emerging corridors.

The Lekki–Epe axis has become a particularly significant development frontier, surrounded by major infrastructure and economic landmarks including the proposed Lekki-Epe International Airport, Alaro City, Pan-Atlantic University, Dangote Refinery and Fertilizer Plant, Lekki Free Trade Zone and Lekki Deep Sea Port.

Harmony Garden’s estate portfolio deliberately sits within this expanding ecosystem.

Its Seven Citadels of Joy comprise GranVille Estate, Lekki Aviation Town, Majestic Bay Estate, The Parliament Estates, Oju-Alaro GRA, HarmonyCasa Estate and HarmonyVille Estate, with HarmonyVille already sold out. The company’s profile states that its land portfolio exceeds 4,600 hectares, with a stated value of more than $380 million.

The significance is not simply the scale.

It is the underlying strategy.

Land as Infrastructure for Tomorrow

Take Lekki Aviation Town.

Located within the Yegunda Resettlement Scheme and directly facing the proposed Lekki-Epe International Airport, the development is positioned around one of the infrastructure projects expected to influence the future character of the corridor.

Then there is GranVille Estate, located at Oreki by Eleko Junction and directly facing the Lekki-Epe Expressway, with proximity to some of the corridor’s most important economic and institutional landmarks.

The Parliament Phase I is positioned within Bolorunpelu-Onigbedu (Oke-Ogun),also directly facing the Lekki-Epe Expressway, Ibeju-Lekki, Lagos State, while HarmonyCasa Phase II occupies Seidu/Imare Airport Government Resettlement Scheme, also facing the proposed international airport and many other high-end strategic locations.

This is where the designation “Land Strategist” becomes particularly fitting.

The strategy is not simply about acquiring land.

It is about understanding the relationship between land, infrastructure, mobility, population growth, and economic expansion.

Beyond Estates: Building Ecosystems

Mosadoluwa’s vision also extends beyond residential development.

His wider business ecosystem spans aviation, logistics, industrial development, agriculture, automobile services, tourism and real estate. His ventures include Royal Crystal Airways, Ibile Industrial Park, Ibile RoyalTrip’s Automobile, and Ibile Food Security Farm City.

That breadth provides an important clue to his approach.

The emerging Lagos cannot be sustained by houses alone.

It needs places to live, places to work, transportation networks, industrial activity, commercial centres, infrastructure, and communities that can grow alongside them.

This is also consistent with Mosadoluwa’s publicly articulated ambition of creating integrated communities rather than simply standalone property developments.

In that sense, his real-estate strategy sits within a much larger nation-building philosophy:

“Empower people, develop land, build legacy.”

Making Homeownership Part of the Strategy

Another defining element of the vision is accessibility.

Through the Ibile Traditional Mortgage System, Harmony Garden has introduced a structured rent-to-own pathway designed to make homeownership more accessible to Nigerians at home and in the diaspora. The model allows an initial 10% commitment, allocation at 30%, move-in at 50%, and repayment of the balance over up to five years at a minimum of 7.5% annual rate.

The significance is bigger than the financing structure itself.

It reflects a belief that urban development should not only create physical communities; it should also create pathways through which ordinary people can participate in those communities.

That people-centred philosophy is central to Mosadoluwa’s broader social-impact work and his stated commitment to expanding homeownership opportunities for Nigerians locally and abroad.

Why the “Lagos Landlord” Is Looking Beyond Today

There is a temptation in real estate to measure success by the number of plots sold, buildings completed or estates launched.

But the more consequential question is different:

What will this location mean 10, 15 or 20 years from now?

That is the question behind strategic land development.

For Mosadoluwa, the answer appears to lie in anticipating the convergence of infrastructure, population, commerce, transportation, and urban expansion, and positioning communities accordingly.

His Seven Citadels of Joy are therefore presented not merely as a collection of estates, but as components of a broader development vision across Lagos.

And that may ultimately be the defining distinction of the Land Strategist.

A conventional developer builds where the city already is.

A strategist studies where the city is going, and begins building there.

The Future Is Being Mapped Today

Lagos will continue to expand.

New roads will open. New economic zones will emerge. New transportation links will reshape commuting patterns. New businesses will follow infrastructure. New communities will rise around them.

The real question is not whether New Lagos will emerge.

It is who will have the foresight to prepare for it.

Hon. (Dr.) Saheed Mosadoluwa is making his answer clear through the scale of his land acquisition, the locations of his developments, his integrated business interests and his focus on expanding access to homeownership.

From aviation to logistics, from land acquisition to estate development, his career has increasingly converged around one central idea:

Understand movement. Identify opportunity. Develop strategically. Build for generations.

That is the story behind Mr. IBILE.

And perhaps the most compelling thing about his strategy is that he is not simply betting on the Lagos of today.

He is positioning for the Lagos that is still becoming.

Media Contact

Organization: Harmony Garden and Estate Development Ltd.

Contact Person: Kabiru Audullahi Mosadoluwa

Website: https://www.landbookbyharmony.com/

Email: Send Email

Address:Wealthstein Adekoya

Country:Nigeria

Release id:48637

The post THE MAN READING LAGOS BEFORE IT ARRIVES appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

Singapore, Singapore, September 1st, 2026, FinanceWire

Voting is now open for the TrustFinance Community Choice Awards 2026, inviting the public to recognize financial companies that have earned their communities’ trust and confidence.

TrustFinance Awards has officially opened voting for the Community Choice Awards 2026, with the public voting period running from 1 September to 31 October 2026. The program gives users and industry communities an opportunity to support shortlisted companies across the global financial services industry.

The Community Choice Awards are built around a simple principle: meaningful recognition should also reflect the voice of the community. While the TrustFinance Performance Awards recognize companies through structured, independent evaluation, the Community Choice Awards place community confidence at the center of the recognition process through public voting.

Shortlisted companies represent a range of financial services sectors, including forex, fintech, investment services, payments, digital assets, and other areas of the financial industry. Voters can explore participating companies and award categories before casting their votes through the official TrustFinance Awards platform.

Community Recognition Through Verified Voting

To support the integrity of the Community Choice Awards, verification measures are incorporated into the voting process to help promote fair participation and reduce fraudulent or manipulated voting activity. The approach is part of TrustFinance Awards’ broader Verified Recognition framework, which focuses on making industry recognition more transparent and verifiable.

“Community trust is one of the strongest forms of recognition a company can earn,” said Peter Bu, CEO of TrustFinance. “The Community Choice Awards give people a direct voice in recognizing the companies they trust, while our verification process helps ensure that recognition is supported by genuine community participation.”

Voting will remain open until 31 October 2026, with the winners of the TrustFinance Community Choice Awards 2026 scheduled to be announced in November 2026.

Review the shortlisted companies and cast a vote at the TrustFinance Awards 2026.

About TrustFinance Awards

TrustFinance Awards is an independent recognition program for the global financial industry. Through its Performance Awards and Community Choice Awards, the program combines structured evaluation, community participation, and digital verification to recognize companies demonstrating excellence, transparency, innovation, customer experience, and public trust.

For more information, users can visit awards.trustfinance.com.

Contact

TrustFinance Awards
TrustFinance
awards@trustfinance.com

Singapore, Singapore, September 1st, 2026, FinanceWire

Voting is now open for the TrustFinance Community Choice Awards 2026, inviting the public to recognize financial companies that have earned their communities’ trust and confidence.

TrustFinance Awards has officially opened voting for the Community Choice Awards 2026, with the public voting period running from 1 September to 31 October 2026. The program gives users and industry communities an opportunity to support shortlisted companies across the global financial services industry.

The Community Choice Awards are built around a simple principle: meaningful recognition should also reflect the voice of the community. While the TrustFinance Performance Awards recognize companies through structured, independent evaluation, the Community Choice Awards place community confidence at the center of the recognition process through public voting.

Shortlisted companies represent a range of financial services sectors, including forex, fintech, investment services, payments, digital assets, and other areas of the financial industry. Voters can explore participating companies and award categories before casting their votes through the official TrustFinance Awards platform.

Community Recognition Through Verified Voting

To support the integrity of the Community Choice Awards, verification measures are incorporated into the voting process to help promote fair participation and reduce fraudulent or manipulated voting activity. The approach is part of TrustFinance Awards’ broader Verified Recognition framework, which focuses on making industry recognition more transparent and verifiable.

“Community trust is one of the strongest forms of recognition a company can earn,” said Peter Bu, CEO of TrustFinance. “The Community Choice Awards give people a direct voice in recognizing the companies they trust, while our verification process helps ensure that recognition is supported by genuine community participation.”

Voting will remain open until 31 October 2026, with the winners of the TrustFinance Community Choice Awards 2026 scheduled to be announced in November 2026.

Review the shortlisted companies and cast a vote at the TrustFinance Awards 2026.

About TrustFinance Awards

TrustFinance Awards is an independent recognition program for the global financial industry. Through its Performance Awards and Community Choice Awards, the program combines structured evaluation, community participation, and digital verification to recognize companies demonstrating excellence, transparency, innovation, customer experience, and public trust.

For more information, users can visit awards.trustfinance.com.

Contact

TrustFinance Awards
TrustFinance
awards@trustfinance.com

United Kingdom, 1st Sep 2026 – Triple-glazed self-cleaning rooflights are becoming an increasingly popular choice for UK homeowners looking to improve natural daylight, thermal performance, and everyday convenience. Therefore, Skylights Rooflanterns is highlighting its premium roof glazing solutions for homeowners, architects, and property professionals across the UK.

Based in London, Skylights Rooflanterns provides high-performance rooflights and roof lantern systems designed for extensions, renovations, kitchens, living areas, and contemporary new-build properties. Additionally, advanced glazing options can help homeowners achieve a brighter interior while supporting improved insulation and reduced maintenance.

Why triple-glazed and self-cleaning rooflights are in demand

Modern homeowners are placing greater emphasis on energy efficiency, comfort, and long-term practicality when choosing products for home improvements. However, roof glazing needs to deliver more than natural light, which is why advanced glazing technologies are becoming increasingly important.

Skylights Rooflanterns offers roof glazing solutions designed to help homeowners achieve:

• Increased natural daylight in kitchens, extensions, and open-plan living areas
• Enhanced thermal performance through advanced triple glazing
• Improved comfort by helping reduce heat transfer through the roof glazing
• Lower maintenance requirements with self-cleaning glass technology
• A clean, contemporary appearance suited to modern architectural designs

“Triple glazing and self-cleaning glass provide practical performance benefits while helping create brighter, more comfortable spaces. Our aim is to give customers roof glazing solutions that work beautifully and perform reliably over the long term.”

High-performance rooflights designed for modern homes

Triple-glazed rooflights are designed with multiple panes of glass to provide enhanced insulation compared with traditional glazing configurations. As a result, they can be an attractive option for homeowners looking to improve the thermal performance of extensions and other areas with large areas of roof glazing.

Self-cleaning glass for reduced maintenance

Self-cleaning glass provides an additional practical advantage for roof glazing. Its specially treated external surface helps water spread across the glass, allowing rainfall to assist in removing dirt and organic deposits.

Consequently, homeowners can spend less time maintaining hard-to-reach roof glazing while continuing to enjoy clear, bright interiors.

Designed for comfort, efficiency, and natural daylight

Modern rooflights are increasingly being specified as part of energy-conscious home improvements. Triple glazing can help improve insulation, while carefully designed rooflight systems allow natural daylight to reach areas that may otherwise depend heavily on artificial lighting.

Additionally, sleek profiles and contemporary glazing designs allow rooflights to complement modern extensions, renovations, and architectural projects.

Why choose Skylights Rooflanterns for rooflight projects in the UK

Skylights Rooflanterns is a UK supplier of rooflights, roof lanterns, flat glass rooflights, and bespoke roof glazing solutions. Consequently, homeowners, architects, and builders can access high-quality glazing options designed around the requirements of individual projects.

Explore the full collection here:

• https://skylights-rooflanterns.co.uk/collections/roof-lanterns
• https://skylights-rooflanterns.co.uk/collections/flat-rooflights
• https://skylights-rooflanterns.co.uk/products/flat-glass-rooflight-custom

About Skylights Rooflanterns

Skylights Rooflanterns is a UK supplier of bespoke rooflight and roof lantern systems for residential and commercial properties. The company provides a range of glazing solutions designed to bring more natural daylight into modern spaces while supporting thermal performance, durability, and contemporary aesthetics.

Contact details

Danny Bhuva
Founder, Skylights Rooflanterns
Email: sales@skylights-rooflanterns.co.uk
Phone: 020 4538 3079
Website: https://skylights-rooflanterns.co.uk/

Call to action: Visit the website to explore triple-glazed, self-cleaning, flat glass rooflight, and bespoke roof glazing solutions for your next project.

Media Contact

Organization: Skylights Roof Lanterns

Contact Person: Danny Bhuva

Website: https://skylights-rooflanterns.co.uk

Email: Send Email

Contact Number: +442045383079

Address:Elizabeth House, 54–58 High Street, Edgware, HA8 7TT

Country:United Kingdom

Release id:48654

The post Triple-Glazed Self-Cleaning Rooflights Lead Customer Demand as Homeowners Invest in Smarter Roof Glazing appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

Raleigh, United States, September 1st, 2026, FinanceWire

Together with the previously announced Talicia strategic divestiture, the acquisition from Ferring of commercialization rights to two larger, proprietary, established gastrointestinal (GI) FDA-approved drugs that together generated approximately $37.5 million in 2025 net sales, completes a major strategic repositioning of RedHill’s commercial GI business

The divestiture of Talicia and the acquisition of the new GI products from Ferring create a catalyst for commercial growth through a materially larger GI business under RedHill’s control, with a significantly stronger liquidity position and provides additional growth and expansion opportunities

Under the terms of the agreement, RedHill obtained the exclusive commercialization rights for an upfront payment to Ferring of $12 million plus potential future milestones and tiered royalties.

The $12 million upfront payment is fully funded through the previously announced $18 million Talicia divestment, with RedHill securing exclusive global and U.S. commercialization rights to Ferring’s Rebyota and Clenpiq, respectively – two synergistic, revenue-generating, FDA-approved GI drugs

Rebyota is a proprietary, first and only single-dose FDA-approved Fecal Microbiota Transplant (FMT for prevention of recurrent C. diff infection (rCDI). FDA-approved in 2022 and Health Canada-approved in 2025, Rebyota, was granted a Breakthrough Therapy and received Orphan Drug designations and generated approximately $16.9 million in 2025 U.S. net sales

Proprietary Clenpiq, a ready-to-use (no mixing required) low-volume bowel preparation on the U.S. market, generated $20.6 million in U.S. 2025 net sales with minimal promotion 

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced the transformational acquisition of exclusive global and U.S. commercialization rights to Rebyota and Clenpiq, from Ferring Pharmaceuticals (“Ferring”), as part of Ferring’s ongoing strategic refocusing.

Dror Ben-Asher, RedHill’s Chief Executive Officer, said: “We have executed a clear strategic sequence. We have monetized Talicia for $18 million cash upfront, plus $35 million in potential upside, used $12 million to secure commercialization rights to two established, proprietary, FDA-approved gastrointestinal drugs, that collectively generated approximately $37.5 million in U.S. net sales in 2025, and emerged with a materially larger, fully controlled commercial business and a stronger liquidity position. Rebyota and Clenpiq are expected to generate a positive cash contribution to RedHill. This, combined with RedHill’s experienced and lean commercial team and proven development capabilities, creates a scalable foundation for further growth, including additional acquisition of complementary revenue-generating products.” Mr. Ben-Asher added: “We thank Ferring for a smooth process to date and look forward to a successful collaboration.”

Under the terms of the agreement, RedHill obtained an exclusive global commercialization license of Rebyota and an exclusive U.S. commercialization license of Clenpiq, for an upfront payment to Ferring of $12 million, plus tiered royalties on net sales and potential milestones. Ferring retains its Rebyota manufacturing facilities, and Ferring will continue to supply Rebyota through the term of the agreement.

“Rebyota is a first-in-class microbiota-based therapy for prevention of recurrent Clostridioides difficile (C. diff) infection (rCDI) in individuals 18 years of age and older following antibiotic treatment for rCDI. FDA-approved in 2022, it generated approximately $16.9 million in U.S. net sales in 2025 through its clinical profile, broad coverage and an established customer base of approximately 600 active accounts,” said Rick Scruggs, RedHill’s Chief Commercial Officer. “Clenpiq, a ready-to-drink low-volume bowel preparation on the U.S. market, delivered $20.6 million in net sales in 2025, with minimal promotion. Together the two assets give RedHill a significantly stronger commercial growth engine in both the U.S. and other new territories.”

C. diff (CDI) infection is a distressing and life-threatening condition – in developed countries it is the most common cause of healthcare-associated (HA) diarrhea. An estimated 3.6 million cases of CDI occur globally each year, including approximately half a million cases in the U.S. 30,000 Americans die every year due to CDI, with a global mortality rate of 1-in-10, rising to almost 1-in-3 in high-risk settings1. In the U.S., up to approximately 165,000 CDI cases result in one or more recurrences, indicating the need for use of prevention strategies.

Rebyota’s one-time administration, which requires no fasting, bowel prep or extended treatment timeframe, has demonstrated more than a 70% success rate at preventing rCDI. An aging population and accompanying increasing hospital-acquired vulnerabilities will likely increase this need. A streamlined ordering and reimbursement process is already in place for physicians, and broad and improving U.S. payer coverage means that 93% of lives have coverage including 43% with coverage after 1st recurrence.

Rebyota, which was granted, Breakthrough Therapy and Orphan Drug designations – with exclusivities and other patent protections that could run to 2036, provides multiple growth opportunities, including recent approval in Canada. The existing approvals also provide the potential for additional approvals in other territories.

Colonoscopy is the cornerstone of GI practice, with more than 15 million colonoscopies performed in the U.S. annually. This number is rising, with follow-up needed after noninvasive screening tests that yield a positive result, an aging population, and guidelines that recommend testing at age 45 instead of age 50, contributing to an increased need for colonoscopy. Bowel preparation is not a pleasant process and is often poorly performed.

Clenpiq is a ready-to-drink low-volume bowel prep. Clenpiq is readily available to patients and has broad commercial and government payer coverage: More than 108 million lives (63%) with unrestricted (no prior approval) have commercial coverage, including 57 million (33%) with preferred position. 23m lives (41%) of Medicare Part D lives have unrestricted access to Clenpiq, including 12m (21%) lives with preferred position5.

RedHill was advised by Morningstar Law Group and Greenberg Traurig LLP on this transaction.

About RedHill Biopharma  

RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill promotes the FDA-approved gastrointestinal therapies Rebyota, for the prevention of recurrent C. diff infection (rCDI), and the bowel preparation treatment, Clenpiq. RedHill’s key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anti-inflammatory, antiviral, metabolic and anticancer activity, targeting multiple indications with a track record of U.S. government and academic collaborations intended for medical countermeasure development including for EVD, radiation exposure indications such as GI-Acute Radiation Syndrome (GI-ARS), a Phase 2/3 program for hospitalized COVID-19, and an ongoing Phase 2 study in prostate cancer in combination with darolutamide; (ii) RHB-102 (Bekinda), with a planned Phase 2 proof-of-concept study for GLP-1/GIP receptor agonist-associated GI intolerance, positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results from a U.S. Phase 2 study for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals (EBR: HYL) for worldwide development and commercialization outside North America; (iii) RHB-204, a next-generation optimized formulation of RHB-104, with a planned Phase 2 study for Crohn’s disease (based on RHB-104’s positive Phase 3 Crohn’s disease study results); and (iv) RHB-107 (upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness, including COVID-19 and also targeting multiple cancer and inflammatory gastrointestinal diseases.

More information about the Company is available at www.redhillbio.com / X.com/RedHillBio.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words, and include, among others, statements regarding the divestment of Talicia and the potential use of the proceeds of such sale; the expected benefits of the acquisition of commercialization rights to Rebyota and Clenpiq, the anticipated commercial growth and cash contribution from these products, expectations regarding market share growth, anticipated payer coverage, the Company’s strategic repositioning and path to operational profitability, potential use of milestone and royalty payments, and the Company’s ability to successfully commercialize Rebyota and Clenpiq. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. 

[i] Akorful RAA, Odoom A, Awere-Duodu A, Donkor ES. The Global Burden of Clostridioides difficile Infections, 2016-2024: A Systematic Review and Meta-Analysis. Infect Dis Rep. 2025 Apr 14;17(2):31. doi: 10.3390/idr17020031. PMID: 40277958; PMCID: PMC12026862.

[ii] Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, Wilson LE, Winston LG, Cohen JA, Limbago BM, Fridkin SK, Gerding DN, McDonald LC. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015 Feb 26;372(9):825-34. doi: 10.1056/NEJMoa1408913. PMID: 25714160; PMCID: PMC10966662.

[iii] Feuerstadt P, Theriault N, Tillotson G. The burden of CDI in the United States: a multifactorial challenge. BMC Infect Dis. 2023 Mar 7;23(1):132. doi: 10.1186/s12879-023-08096-0. PMID: 36882700; PMCID: PMC9990004.

[iv] Khanna S, Assi M, Lee C, et al. Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a Bayesian primary analysis for the prevention of recurrent Clostridioides difficile infection. Drugs. 2022;82(15):1527-1538. doi:10.1007/s40265-022-01797-x.

[v] Data on file. Ferring Pharmaceuticals

[vi] MarketScan Commercial Claims and Encounters and Medicare Supplemental database

Contact

Chief Corporate and BD Officer
Adi Frish
RedHill Biopharma
adi@redhillbio.com